2 active not recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation Tocilizumab, Fludarabine, Melphalan - Hematologic Malignancy, Bone Marrow Transplant | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 21 | 2020-10-07 | 2026-01-06 |
| Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia CliniMACS® TCRαβ/CD19 Combined Depletion System - Myelodysplasia, Hematologic Malignancy | Phase 1 / Phase 2 | Active not recruiting | Nationwide Children's Hospital | 20 | 2018-03-02 | 2026-04-03 |
Hematologic Neoplasms (2) · Anemia, Refractory, with Excess of Blasts (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Anemia (1) · Anemia, Refractory (1) · Bone Marrow Diseases (1) · Myelodysplastic Syndromes (1)
Antilymphocyte Serum (1) · Melphalan (1) · Whole-Body Irradiation (1) · fludarabine (1) · fludarabine phosphate (1) · thymoglobulin (1) · tocilizumab (1)
Nationwide Children's Hospital (1) · Weill Medical College of Cornell University (1)
United States (2)